These thyroid function tests are normal and do not indicate hypothyroidism
With a TSH of 2.4 mIU/L and free T4 of 1.27 ng/dL, this 82-year-old patient has normal thyroid function and should NOT be started on thyroid-specific therapy. His fatigue must be attributed to other causes among his multiple comorbidities.
Why These Results Are Normal
The patient's TSH of 2.4 mIU/L falls well within the established normal reference range of 0.45-4.12 mIU/L 1, 2. His free T4 of 1.27 ng/dL is also within normal limits. By definition, hypothyroidism requires either:
- Overt hypothyroidism: Elevated TSH with LOW free T4
- Subclinical hypothyroidism: TSH >4.5 mIU/L with normal free T4 2
This patient meets neither criterion.
The TSH Controversy Does Not Apply Here
Some have proposed lowering the upper TSH threshold to 2.5 mIU/L, but the 2012 AACE/ATA guidelines explicitly reject this approach 1. The guideline states that while TSH values between 2.5-4.12 mIU/L may represent early hypothyroidism in some individuals, data to support treating patients in this range are lacking (except during pregnancy). Adopting a 2.5 mIU/L cutoff would lead to over 10 million additional hypothyroidism diagnoses in the U.S. annually without clear clinical benefit 1.
The mean TSH in healthy populations is approximately 1.4-1.5 mIU/L, and normal individuals experience up to 50% day-to-day variation in TSH values 1, 2. A patient with a mean TSH just above 1.5 mIU/L would frequently be misclassified as hypothyroid if the upper limit were 2.5 mIU/L 1.
Special Considerations in This Elderly Patient with CKD
Age-Related TSH Changes
TSH naturally increases with age—12% of persons aged ≥80 years without thyroid disease have TSH >4.5 mIU/L 2. The standard population reference interval may be inappropriate for older adults 2, 3.
Chronic Kidney Disease Effects
This is critical: Advanced CKD frequently produces thyroid test patterns that can mimic hypothyroidism 4. In patients with CKD stages 3-5, subclinical hypothyroidism prevalence increases with declining renal function 5. However, this patient's TSH of 2.4 mIU/L does not even meet the threshold for subclinical hypothyroidism.
Recent evidence emphasizes that CKD-related, volume-related, and medication-related factors can alter thyroid tests without representing true thyroid failure 4. The clinical challenge is distinguishing persistent thyroid disease from uremic mimics before committing vulnerable patients to long-term levothyroxine 4.
Other Causes of Fatigue to Investigate
In this patient with diabetes, CKD, elevated liver enzymes, dyslipidemia, and mild anemia, the fatigue is far more likely attributable to:
- Anemia (which can be worsened by hypothyroidism but is present here without thyroid dysfunction) 6
- Uremia from advanced CKD
- Diabetes-related complications
- Hepatic dysfunction
- Cardiovascular disease
- Medication effects
When Treatment Would Be Indicated
Treatment should only be considered if:
- TSH persistently >10 mIU/L (even with normal free T4), given associations with cardiovascular mortality and heart failure in elderly patients 7, 8
- TSH 7-10 mIU/L with cardiovascular risk factors, based on observational data showing increased mortality risk 7
- TSH >4.5 mIU/L with low free T4 (overt hypothyroidism)
Common Pitfalls to Avoid
- Do not treat based on a single borderline TSH value 1, 2
- Do not use symptoms alone to diagnose hypothyroidism—symptoms like fatigue are nonspecific and common in elderly patients with multiple comorbidities 2
- Avoid overtreatment with levothyroxine, which occurs in 20% of treated patients and carries cardiovascular and skeletal risks, particularly in the elderly 1
- In hospitalized or acutely ill patients, defer thyroid testing unless there is strong clinical suspicion, as acute illness can transiently alter TSH 1, 9
Recommendation
No thyroid-specific therapy is indicated. Focus diagnostic efforts on the patient's anemia, CKD progression, glycemic control, and hepatic dysfunction as more likely contributors to his fatigue. If thyroid dysfunction is suspected in the future, repeat TSH and free T4 after optimizing volume status and systemic illness, at a consistent point relative to any dialysis cycle 4.